Building on rare disease applications to apply drug sensitivity testing to high-incidence forms of cancer
Biocerta is developing functional drug sensitivity testing in rare cancers first, where clinical need is high and regulatory processes may be accelerated. This work creates the foundation for expanding the platform to more common forms of cancers.
